Immunological mechanisms underlie certain states of pathological neutropenia (Walford, 1960) . With leucoagglutination assays some success has been achieved in the demonstration of humoral autoimmunity to target cell antigens present on granulocytes (Walford, 1960; Lalezari, 1966) . However, in the majority of suspected cases of immune neutropenia leucoagglutinins are not found (Pisciotta, 1973) .
Agranulocytosis is an uncommon but serious side effect of the use of the immunostimulant drug levamisole . Immunological mechanisms are suspected to account for the neutropenia, and autoagglutinins have been found in the serum of some affected individuals (Rosenthal et al., 1976) . Using a modified complement-dependent microgranulo-cytotoxicity assay (Drew et al., 1977) similar to that employed to serotype lymphocytes (Mittal et al., 1968) we have detected the presence of autoimmune and nonagglutinating granulocytotoxins in 3 patients with severe neutropenia who were receiving levamisole. Patient 3. Serum drawn at the time of the neutropenic episode was cytotoxic for 100 % of the patient's autologous granulocytes (titre 1:8) and the panel of granulocytes (CS =100), whereas serum obtained before and after the leucopenic event was noncytotoxic for the panel (CS=0) and autologous granulocytes.
Serum samples from two groups of bladder cancer subjects were tested against the same panel (n=33) of random granulocytes (Fig. 3) 
Discussion
Autoimmune and cytotoxic granulocyte antibodies were present in the sera of all 3 bladder cancer patients who developed neutropenia while receiving levamisole therapy. The occurrence of granulocyte antibodies appeared to be causally related to the onset of the leucopenia in that sera before and after the neutropenic episode had no granulocytotoxic activity. In comparison with a control group of patients not receiving levamisole granulocyte autoantibodies occurred much more frequently (P <0 06) in the sera of patients on levamisole. This finding supports an association between levamisole, neutropenia, and the presence of granulocytotoxic antibodies.
That the granulocytotoxic autoreactivity at the time of the neutropenic episodes is an artefact of the in-vitro assay is very unlikely. This is because less than 5 % dead cells were noted in the control wells with non-cytotoxic sera and control experiments clearly showed the in-vitro cytotoxic reactions to be both antibody-mediated and complementdependent. The failure of the cytotoxic antisera to agglutinate autologous granulocytes serves to distinguish granulocytotoxic antibodies from autoagglutinins reported in a number of patients with agranulocytosis or levamisole therapy (Rosenthal et al., 1976; Graber et al., 1976; Parkinson et al., 1977) . Furthermore, the demonstration of autocytotoxicity did not require the presence of levamisole in vitro. The cytotoxic specificity of the granulocyte autoantibodies was restricted to peripheral blood neutrophils, whereas autologous red blood cells, T and B lymphocytes, and monocytes were unreactive (Drew et al., 1978) . The spontaneous restoration of peripheral blood neutrophil counts in the 3 cases cited is consistent with our failure to demonstrate granulocyte antigens on colony-forming myeloid stem cells (CFU-C) and early granulocyte precursor cells in preparation.
The role of levamisole in the neutropenic response is at present unknown. We have found that granulocyte antibodies predominated in patients on levamisole and that neutropenia was restricted to patients with granulocytotoxins and receiving levamisole. In addition to promoting antibody production it is possible that levamisole also adversely alters the susceptibility of the target cell to immune sensitisation and subsequent destruction. However, the absence of neutropenia in 3 patients with granulocytotoxins on levamisole therapy (Fig. 3) as well as the occurrence of neutropenia in patients with granulocyte autoantibodies and not receiving levamisole (unpublished) suggests that additional factors as yet undefined play an important supplementary role in the pathogenesis of the autoimmune neutropenia. As we have been unable to detect any immunochemical differences in granulocyte autoantibodies in non-neutropenic subjects versus patients with granulocytopenia, it is our postulate that the occurrence of neutropenia is governed by some inherent defect(s) at the target cell level which promotes the immune destruction of granulocytes. We are now testing this hypothesis.
The greater use of levamisole (Symoens and Rosenthal, 1977) puts a larger population of patients at risk for the development of neutropenia. As the appearance of granulocytotoxins during a course of levamisole therapy may in some cases herald lifethreatening neutropenia, screening for these antibodies may opportunely alert the clinician of adverse sequelae in the treated patient population. 
